|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Di Bisceglie AM, Rustgi VK, Hoofnagle JH,
Dusheiko GM and Lotze MT: NIH conference. Hepatocellular carcinoma.
Ann Intern Med. 108:390–401. 1998. View Article : Google Scholar
|
|
5
|
But DY, Lai CL and Yuen MF: Natural
history of hepatitis-related hepatocellular carcinoma. World J
Gastroenterol. 14:1652–1656. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dubbelboer IR, Lilienberg E, Ahnfelt E,
Sjögren E, Axén N and Lennernäs H: Treatment of intermediate stage
hepatocellular carcinoma: A review of intrahepatic doxorubicin
drug-delivery systems. Ther Deliv. 5:447–466. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Villanueva A, Minguez B, Forner A, Reig M
and Liovet JM: Hepatocellular carcinoma: Novel molecular approaches
for diagnosis, prognosis, and therapy. Annu Rev Med. 61:317–328.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li WX, Chen LP, Sun MY, Li JT, Liu HZ and
Zhu W: 3′3-Diindolylmethane inhibits migration, invasion and
metastasis of hepatocellular carcinoma by suppressing FAK
signaling. Oncotarget. 6:23776–23792. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Villanueva A, Newell P, Chiang DY,
Friedman SL and Llovet JM: Genomics and signaling pathways in
hepatocellular carcinoma. Semin Liver Dis. 27:55–76. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kudo N, Khochbin S, Nishi K, Kitano K,
Yanagida M, Yoshida M and Horinouchi S: Molecular cloning and cell
cycle-dependent expression of mammalian CRM1, a protein involved in
nuclear export of proteins. J Biol Chem. 272:29742–29751. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nguyen KT, Holloway MP and Altura RA: The
XPO1 nuclear export protein in normal development and disease. Int
J Biochem Mol Biol. 3:137–151. 2012.PubMed/NCBI
|
|
12
|
Turner JG, Dawson J and Sullivan DM:
Nuclear export of proteins and drug resistance in cancer. Biochem
Pharmacol. 83:1021–1032. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Muqbil I, Bao B, Abou-Samra AB, Mohammad
RM and Azmi AS: Nuclear export mediated regulation of MicroRNAs:
Potential target for drug intervention. Curr Drug Targets.
14:1094–1100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Siddiqui N and Borden KL: mRNA export and
cancer. Wiley Interdiscip Rev RNA. 3:13–25. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Santiago A, Li D, Zhao LY, Godsey A and
Liao D: p53 SUMOylation promotes its nuclear export by facilitating
its release from the nuclear export receptor CRM1. Mol Biol Cell.
24:2739–2752. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brodie KM and Henderson BR:
Characterization of BRCA1 protein targeting, dynamics, and function
at the centrosome: A role for the nuclear export signal, CRM1, and
Aurora A kinase. J Biol Chem. 287:7701–7716. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chan KS, Wong CH, Huang YF and Li HY:
Survivin withdrawal by nuclear export failure as a physiological
switch to commit cells to apoptosis. Cell Death Dis. 1:e572010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mariano AR, Colombo E, Luzi L, Martinelli
P, Volorio S, Bernard L, Meani N, Bergomas R, Alcalay M and Pelicci
PG: Cytoplasmic localization of NPM in myeloid leukemias is
dictated by gain-of-function mutations that create a functional
nuclear export signal. Oncogene. 25:4376–4380. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Henderson BR: Nuclear-cytoplasmic
shuttling of APC regulates beta-catenin subcellular localization
and turnover. Nat Cell Biol. 2:653–660. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishizawa J, Kojima K, Hail N Jr, Tabe Y
and Andreeff M: Expression, function, and targeting of the nuclear
exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol
Ther. 153:25–35. 2015.PubMed/NCBI
|
|
21
|
Xu D, Grishin NV and Chook YM: NESdb: A
database of NES-containing CRM1 cargoes. Mol Biol Cell.
23:3673–3676. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fabregat I: Dysregulation of apoptosis in
hepatocellular carcinoma cells. World J Gastroenterol. 15:513–520.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chiorazzi N: Cell proliferation and death:
Forgotten features of chronic lymphocytic leukemia B cells. Best
Pract Res Clin Haematol. 20:399–413. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fulda S and Debatin KM: Apoptosis pathways
in neuroblastoma therapy. Cancer Lett. 197:131–135. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Giovanni GL, Senapedis W, McCauley D,
Baloglu E, Shacham S and Festuccia C: Nucleo-cytoplasmic tansport
as a therapeutic target of cancer. J Hematol Oncol. 7:852014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hamamoto T, Uozumi T and Beppu T:
Leptomycins A and B, new antifungal antibiotics. III. Mode of
action of leptomycin B on Schizosaccharomyces pombe. J Antibiot
(Tokyo). 38:1573–1580. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meissner T, Krause E and Vinkemeier U:
Ratjadone and leptomycin B block CRM1-dependent nuclear export by
identical mechanisms. FEBS Lett. 576:27–30. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mutka SC, Yang WQ, Dong SD, Ward SL, Craig
DA, Timmermans PB and Murli S: Identification of nuclear export
inhibitors with potent anticancer activity in vivo. Cancer
Res. 69:510–517. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Etchin J, Sanda T, Mansour MR, Kentsis A,
Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, et
al: KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has
selective anti-leukaemic activity in preclinical models of T-cell
acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J
Haematol. 161:117–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gao W, Lu C, Chen L and Keohavong P:
Overexpression of CRM1: A characteristic feature in a transformed
phenotype of lung carcinogenesis and a molecular target for lung
cancer adjuvant therapy. J Thorac Oncol. 10:815–825. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang X, Cheng L, Yao L, Ren H, Zhang S,
Min X, Chen X, Zhang J and Li M: Involvement of chromosome region
maintenance 1 (CRM1) in the formation and progression of esophageal
squamous cell carcinoma. Med Oncol. 31:1552014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu X, Niu M, Xu X, Cai W, Zeng L, Zhou X,
Yu R and Xu K: CRM1 is a direct cellular target of the natural
anti-cancer agent plumbagin. J Pharmacol Sci. 124:486–493. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Walker CJ, Oaks JJ, Santhanam R, Neviani
P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail
NY, et al: Preclinical and clinical efficacy of XPO1/CRM1
inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Blood. 122:3034–3044. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Theise ND, Curado MP, Franceschi S, et al:
Hepatocellular carcinoma. Classification of tumours of the
digestive system (4th). Bosman FT, Carneiro F, Hruban RH and Theise
ND: IARC. (Lyon). 2010.205
|
|
35
|
Jain D: Tissue diagnosis of hepatocellular
carcinoma. J Clin Exp Hepatol. 4(Suppl 3): S67–S73. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fleming ID: AJCC/TNM cancer staging,
present and future. J Surg Oncol. 77:233–236. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Farazi PA and DePinho RA: Hepatocellular
carcinoma pathogenesis: From genes to environment. Nat Rev Cancer.
6:674–687. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Stade K, Ford CS, Guthrie C and Weis K:
Exportin 1 (Crm1p) is an essential nuclear export factor. Cell.
90:1041–1050. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ma HX, Shu QH, Pan JJ, Liu D, Xu GL, Li
JS, Ma JL, Jia WD, Yv JH and Ge YS: Expression of Kindlin-1 in
human hepatocellular carcinoma and its prognostic significance.
Tumor Biol. 36:4235–4241. 2015. View Article : Google Scholar
|
|
40
|
Yang X, Cheng L, Yao L, Ren H, Zhang S,
Min X, Chen X, Zhang J and Li M: Involvement of chromosome region
maintenance 1 (CRM1) in the formation and progression of esophageal
squamous cell carcinoma. Med Oncol. 31:1152014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
van der Watt PJ, Maske CP, Hendricks DT,
Parker ML, Denny L, Govender D, Birrer MJ and Leanner VD: The
Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed
in cervical cancer and are critical for cancer cell survival and
proliferation. Int J Cancer. 124:1829–1840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shen A, Wang Y, Zhao Y, Zou L, Sun L and
Cheng C: Expression of CRM1 in human gliomas and its significance
in p27 expression and clinical prognosis. Neurosurgery. 65:153–159;
discussion 159–160. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen L, Moore JE, Samathanam C, Shao C,
Cobos E, Miller Ms and Gao W: CRM1-dependent p53 nuclear
accumulation in lung lesions of a bitransgenic mouse lung tumor
model. Oncol Rep. 26:223–228. 2011.PubMed/NCBI
|
|
44
|
Noske A, Weichert W, Niesporek S, Röske A,
Buckendahl AC, Koch L, Sehouli J, Dietel M and Denkert C:
Expression of the nuclear export protein chromosomal region
maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian
cancer. Cancer. 112:1733–1743. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH
and Sun YL: Prognostic value of CRM1 in pancreas cancer. Clin
Invest Med. 32:E3152009.PubMed/NCBI
|
|
46
|
Lapalombella R, Sun Q, Williams K,
Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta
S, et al: Selective inhibitors of nuclear export showed that
CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood.
120:4621–4634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tai YT, Landesman Y, Acharya C, Calle Y,
Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, et
al: CRM1 inhibition induces tumor cell cytotoxicity and impairs
osteoclastogenesis in multiple myeloma: Molecular mechanisms and
therapeutic implications. Leukemia. 28:155–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kojima K, Kornblau SM, Ruvolo V, Dilip A,
Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, et al:
Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
Blood. 121:4166–4174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Schmidt J, Braggio E, Kortuem KM, Egan JB,
Zhu YX, Xin CS, Tiedemann RE, Palmer SE, Garbitt VM, McCauley D, et
al: genome-wide studies in multiple myeloma identify XPO1/CRM1 as a
critical target validated using the selective nuclear export
inhibitor KPT-276. Leukemia. 27:2357–2365. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Azmi AS, Al-Katib A, Aboukameel A,
McCauley D, Kauffman M, Shacham S and Aohammad RM: Selective
inhibitors of nuclear export for the treatment of non-Hodgkin's
lymphomas. Haematologica. 98:1098–1106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Walker CJ, Oaks JJ, Santhanam R, Neviani
P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail
NY, et al: Preclinical and clinical efficacy of XPO1/CRM1
inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Blood. 122:3034–3044. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Forgues M, Marrogi AJ, Spillare EA, Wu CG,
Yang Q, Yoshida M and Wang XW: Interaction of the hepatitis B virus
X protein with the Crm1-dependent nuclear export pathway. J Biol
Chem. 276:22797–22803. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chuanxin Zou, Jiayan Nie, Shaojun Dai, et
al: Study of relationships between primary carcinoma of the liver
and chronic hepatitis B with positive/negative HBeAg. World Chinese
Journal of Digestology. 16:3696–3699. 2008.
|
|
54
|
Biselli M, Conti F, Gramenzi A, Frigerio
M, Cucchetti A, Fatti G, D'Angelo M, Dall'Agata M, Giannini EG, et
al: A new approach to the use of α-fetoprotein as surveillance test
for hepatocellular carcinoma in patients with cirrhosis. Br J
Cancer. 112:69–76. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ishizuka M, Kubota K, Kita J, Shimoda M,
Kato M, Mori S, Iso Y, Yamagishi H and Kojima M: Aspartate
aminotransferase-to-platelet ratio index is associated with liver
cirrhosis in patients undergoing surgery for hepatocellular
carcinoma. J Surg Res. 194:63–68. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang FS, Fan JG, Zhang Z, Gao B and Wang
HY: The global burden of liver disease: The major impact of China.
Hepatology. 60:2099–2108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Pascale RM, Simile MM, Calvisi DF, Frau M,
Muroni MR, Seddaiu MA, Daino L, Muntoni MD, De Miglio MR,
Thorgeirsson SS and Feo F: Role of HSP90, CDC37, and CRM1 as
modulators of P16(INK4A) activity in rat liver carcinogenesis and
human liver cancer. Hepatology. 42:1310–1319. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ma WJ, Wang HY and Teng LS: Correlation
analysis of preoperative serum alpha-fetoprotein (AFP) level and
prognosis of hepatocellular carcinoma (HCC) after hepatectomy.
World J Surg Oncol. 11:2122013. View Article : Google Scholar : PubMed/NCBI
|
